Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Helios Automated IFA System

publication date: Sep 2, 2016
 | 
author/source: AESKU GROUP

AESKU Receives FDA 510(k) Clearance for HELIOS AUTOMATED IFA SYSTEM with AESKUSLIDES ANA HEp-2-Gamma

heliosAESKU.GROUP, a research-focused supplier of innovative products and services for the early detection, diagnosis and prognosis of autoimmune diseases, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new HELIOS AUTOMATED IFA SYSTEM with AESKUSLIDES ANA HEp-2-Gamma Assay. The HELIOS is a new revolutionary platform that employs automated immunofluorescence (IFA) technology to process and analyze patient samples. It is the first clinical diagnostics platform to offer automation of the IFA process to this extent.

The HELIOS is an automated system for immunofluorescence processing with image capturing with an integrated fluorescence microscope and software. Results must be confirmed by a trained user. It is the first and only system that performs this process continuously from start to finish. The HELIOS fully addresses and overcomes the known limitations of IFA, enabling the user to adopt it as the Autoimmunity reference screening method. The HELIOS is currently in use in 29 countries worldwide.

"We are thrilled about receiving FDA clearance for this significant new technology. This unique system will improve turnaround time, eliminate subjectivity and the labor-intensive processes involved in Immunofluorescence assays and finally improve the quality of patient testing. The development of the HELIOS system is a great example of AESKU's commitment to providing useful tools that enable laboratories to improve testing methods, maximize efficiencies and lower costs. To further our commitment to the US market, we have opened manufacturing and R&D facilities in the Buffalo Niagara Medical Campus. We are now able to give our customers even more technical support and timely products manufactured in the US. With the HELIOS, darkrooms are no longer required," said Dr. Matthias, founder and CEO of the AESKU.GROUP.

“In 2009, the American College of Rheumatology (ACR) published a position statement, asserting that IFA was the Gold Standard for screening for systemic autoimmune disease. Since then, Dr. Matthias and the AESKU.GROUP have strived to develop a platform that would address the needs of clinical laboratories for more automation and less subjectivity in IFA. We look forward to making it available to US clinical laboratories with the help of Grifols, our exclusive distributor in the US,” said Bruno Larida, Vice-President AESKU. INC and US Country Manager.

The HELIOS AUTOMATED IFA SYSTEM is initially cleared for use with AESKUSLIDES ANA HEp-2-Gamma assay and the next assays to be cleared are: ANCA, Crithidia Luciliae and Tissue Sections.

The system is displayed at the American Association of Clinical Chemistry meeting and is now available in the U.S.


more about aesku


 

 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events